Vinpocetine Injection 2ml: 10mg / 2ml: 20mg GMP Certificated Western Medicine

• Customization: Available
• Application: Internal Medicine
• Usage Mode: I.M/I.V
• State: Liquid
• Shape: Injection
• Type: Organic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: Available
• Drug Ad Approval No.: Available
• Factory Inspection: Available
• Packing: Ampoules/Tray/Box
• OEM Service: Available
• MOQ: 5000
• Storage: Keep out of Light, Airtight and in a Cool Place (N
• Quality Standard: Bp, USP
• Shelf Life: 36 Months
• Transport Package: Box/Carton
• Specification: 2ml: 10mg / 2ml: 20mg
• Trademark: Private logo service
• Origin: China
• Production Capacity: 100000000000PCS/Month

Product Description

Vinpocetine Injection

 

PRODUCT NAME	Vinpocetine Injection
Molecular formula	C22H26N2O2
Molecular weight	350.46
PACKING DETAILS:	10 ampoules/tray/box
STORAGE:	Keep out of light, airtight and in a cool place (no more than 20 ºC)
SHELF LIFE:	36 months
Character	Colorless clear liquid
CONSIGNMENT MANUFACTURING, BRAND OEM/ODM SERVICE IS AVAILABLE.

 

Indications
Improve the sequelae of cerebral infarction, cerebral hemorrhage sequelae, cerebral arteriosclerosis and other induced symptoms.

Dosage
Intravenous drip, the initial dose of 20 mg per day, later according to the disease can be increased to 30 mg per day. 20-30mg of this product can be added into 500ml of 0.9% sodium chloride injection or 500ml of 5% glucose injection for slow drip (the drip speed should not exceed 80 drops / min). The prepared infusion should be used within 3 hours. After intravenous drip treatment, oral vinpocetine tablets are recommended to continue treatment. Patients with liver and kidney diseases do not need to adjust the dose.

Adverse reactions
1. Allergies: sometimes there may be rashes, occasionally measles, itching and other allergic symptoms, if there are such symptoms, the drug should be stopped.
2. Mental nervous system: there may be sleep disorders (insomnia, drowsiness), headache, vertigo, fatigue and sweating, occasionally numbness of the side limbs, and aggravation of the sense of detachment.
3. Digestive tract: sometimes nausea, vomiting, heartburn and dry mouth, occasionally loss of appetite, abdominal pain, diarrhea and other symptoms.
4. Circulatory system: it is mainly blood pressure drop, flush, phlebitis. Sometimes can appear dizziness and other symptoms. Occasionally, there may be ST segment depression, QT interval prolongation, tachycardia and premature contraction. Due to their irregular occurrence, the relationship with the treatment of this drug has not been confirmed.
5. Blood: leucopenia may occur sometimes.
6. Liver: sometimes transaminase and alkaline phosphatase increase.
7. Kidney: blood urea nitrogen may be increased occasionally.

Contraindication 
1. It is forbidden to be allergic to any ingredient in this product;
2. In the acute stage of intracranial hemorrhage, it is forbidden to stop bleeding completely after intracranial hemorrhage;
3. Severe ischemic heart disease and arrhythmia are forbidden.

Precautions
1. This product can't be injected intramuscularly, and can't be used intravenously without dilution.
2. Do not dilute with infusion containing amino acid.
3. In vitro hemolysis test results showed that vinpocetine concentration more than 0.06mg/ml hemolysis.
4. The injection is not compatible with heparin, so it is suggested that they should not be mixed in the same syringe, but anticoagulant therapy can be carried out at the same time.
5. If combined with antiarrhythmic drugs, or intracranial pressure rise, arrhythmia and QT prolongation syndrome, the benefits and risks of using this product should be comprehensively weighed. ECG monitoring is recommended for patients with QT interval prolongation syndrome or QT interval prolongation caused by drug treatment.
6. Because the injection contains sorbitol (80mg / ml), the blood glucose level of diabetic patients should be controlled during the treatment, and the patients with fructose intolerance or fructose-1,6-diphosphate deficiency should avoid using it.